nexalin technology inc - NXL

NXL

Close Chg Chg %
0.63 -0.02 -2.59%

Closed Market

0.61

-0.02 (2.59%)

Volume: 417.52K

Last Updated:

Dec 29, 2025, 4:00 PM EDT

Company Overview: nexalin technology inc - NXL

NXL Key Data

Open

$0.61

Day Range

0.58 - 0.67

52 Week Range

0.58 - 3.87

Market Cap

$11.75M

Shares Outstanding

18.65M

Public Float

14.40M

Beta

3.80

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.59

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

177.85K

 

NXL Performance

1 Week
 
-2.59%
 
1 Month
 
-43.18%
 
3 Months
 
-32.57%
 
1 Year
 
-79.20%
 
5 Years
 
N/A
 

NXL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About nexalin technology inc - NXL

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices help people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

NXL At a Glance

Nexalin Technology, Inc.
1776 Yorktown
Houston, Texas 77056
Phone 1-832-260-0222 Revenue 168.72K
Industry Medical Specialties Net Income -7,607,182.00
Sector Health Technology 2024 Sales Growth 52.347%
Fiscal Year-end 12 / 2025 Employees 6
View SEC Filings

NXL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 150.755
Price to Book Ratio 9.988
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.837
Enterprise Value to Sales 130.13
Total Debt to Enterprise Value N/A

NXL Efficiency

Revenue/Employee 28,120.167
Income Per Employee -1,267,863.667
Receivables Turnover 12.936
Total Asset Turnover 0.043

NXL Liquidity

Current Ratio 7.246
Quick Ratio 6.926
Cash Ratio 6.365

NXL Profitability

Gross Margin -810.783
Operating Margin -4,596.138
Pretax Margin -4,511.61
Net Margin -4,508.735
Return on Assets -193.699
Return on Equity -221.053
Return on Total Capital -206.94
Return on Invested Capital -221.053

NXL Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Nexalin Technology Inc - NXL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
144.06K 1.32M 110.75K 168.72K
Sales Growth
-40.69% +817.20% -91.62% +52.35%
Cost of Goods Sold (COGS) incl D&A
250.18K 1.06M 1.41M 1.54M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
537 5.72K 4.25K 15.11K
Depreciation
- 537 5.72K 503
Amortization of Intangibles
- - 3.75K 15.11K
-
COGS Growth
+49.91% +322.62% +33.70% +8.71%
Gross Income
(106.11K) 264.04K (1.30M) (1.37M)
Gross Income Growth
-239.57% +348.82% -593.44% -5.00%
Gross Profit Margin
-73.66% +19.98% -1,176.41% -810.78%
2021 2022 2023 2024 5-year trend
SG&A Expense
5.91M 2.10M 4.39M 6.39M
Research & Development
- 511.00K 1.92M 1.19M
Other SG&A
5.91M 1.59M 2.47M 5.20M
SGA Growth
+77.32% -64.53% +109.50% +45.37%
Other Operating Expense
- - - -
-
Unusual Expense
- (22.92K) (22.92K) (615.00K)
EBIT after Unusual Expense
(6.00M) (1.81M) (5.08M) (7.75M)
Non Operating Income/Expense
- 171.68K 471.42K 142.61K
Non-Operating Interest Income
- - - 3.19K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 82.32K 59.38K 38.84K
Interest Expense Growth
- +4.62% -27.86% -34.60%
Gross Interest Expense
- 82.32K 59.38K 38.84K
Interest Capitalized
- - - -
-
Pretax Income
(6.08M) (1.70M) (4.65M) (7.61M)
Pretax Income Growth
-78.58% +72.07% -173.81% -63.75%
Pretax Margin
-4,218.93% -128.49% -4,197.56% -4,511.61%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(6.08M) (1.70M) (4.65M) (7.61M)
Minority Interest Expense
- - - -
-
Net Income
(6.08M) (1.70M) (4.65M) (7.61M)
Net Income Growth
-78.58% +72.07% -173.81% -63.64%
Net Margin Growth
-4,218.93% -128.49% -4,197.56% -4,508.73%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(6.08M) (1.70M) (4.65M) (7.61M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(6.08M) (1.70M) (4.65M) (7.61M)
EPS (Basic)
-0.8349 -0.233 -0.6251 -0.8254
EPS (Basic) Growth
-78.59% +72.09% -168.28% -32.04%
Basic Shares Outstanding
7.28M 7.29M 7.44M 9.22M
EPS (Diluted)
-0.8349 -0.233 -0.6251 -0.8254
EPS (Diluted) Growth
-78.59% +72.09% -168.28% -32.04%
Diluted Shares Outstanding
7.28M 7.29M 7.44M 9.22M
EBITDA
(6.02M) (1.83M) (5.69M) (7.74M)
EBITDA Growth
-84.72% +69.64% -211.50% -35.97%
EBITDA Margin
-4,177.32% -138.29% -5,139.64% -4,587.18%

Insider Actions for Nexalin Technology Inc - NXL

Date Name Shares Transaction Value
Mar 14, 2025 Carolyn Shelton Sr. VP - Quality, Regulatory 30,000 Open market or private purchase of non-derivative security Non-derivative transaction at $2.2 per share 66,000.00
Feb 28, 2025 Mark White President and CEO; Director 447,427 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mark White President and CEO; Director 1,387,024 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 David Owens Chief Medical Officer; Director 139,821 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 David Owens Chief Medical Officer; Director 794,184 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 David Owens Chief Medical Officer; Director 919,184 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Nexalin Technology Inc in the News